Study Says Misunderstanding Surrounds HIV Vaccine Trials

In at-risk communities better communication is needed around HIV vaccine trials to ensure that those in these at-risk communities understand the process and continue to participate, shows University of Toronto study.

The study – published in the September edition of the American Journal of Public Health – centred around a major international HIV vaccine trial that was called off before completion in 2009. Researchers wanted to know what individuals in high-risk communities understood about the trial and its termination, and how that impacted their willingness to participate in and support future research.

AIDS/HIV Treatment - Drugs - Proteas Inhibitors - NRTIs - NNRTIs
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV

"In order to find a vaccine for HIV, it's essential to have the participation of those in at-risk communities for vaccine trials," says lead author Peter A. Newman, Professor at U of T's Factor-Inwentash Faculty of Social Work. "Our study showed that we're not doing enough to adequately communicate the processes and outcomes of HIV vaccine trials to most-at-risk populations. There is still a lot of misinformation, distrust and misunderstanding out there, which could ultimately lead to people in high-risk communities refusing to participate in trials."

In Toronto and Ottawa, researchers interviewed nine focus groups made up of people from "high-risk" communities. They asked participants about their knowledge of vaccines and vaccine trials – including the cancelled international trial – and probed their understanding of why that trial was called off. Researchers also questioned participants about their willingness to participate in future trials.

A few key themes emerged, according to Newman, who holds the Canada Research Chair in Health and Social Justice at U of T:

Quiz on HIV / AIDS
Statistics tell us that the world HIV+ population has risen drastically from 8 million in 1990 to a whopping 33 million in 2007! Even more alarming is the fact that young people (below the age of 25) account for half of these infections! This is adequate proof for the lack of awareness among the general public even in these modern times. So take our quiz and brush up on the essential facts of HIV/AIDS.

There are 10 questions on HIV / AIDS in this quiz that will explore the depth of your knowledge and provide answers to the following:

Immune control of HIV ()
Symptoms of HIV/AIDS ()
Cure for AIDS ()
Acute HIV syndrome ()
World AIDS day ()
Western blot ()

Many people still believe that vaccine trials involve injecting a small amount of HIV into participants, a falsehood that could affect their willingness to participate in vaccine trials.

HIV/AIDS Risk Calculator
The HIV risk quiz helps you determine risk factors for HIV.

There is a distrust of doctors and medical researchers. The international vaccine trial was called off when researchers discovered a small subset of participants were placed at a higher risk of contracting HIV, but many people didn't believe this was an unforeseen consequence. Some participants believed the doctors/researchers must have been able to predict this consequence, and this reinforced their distrust in the medical system.

There is some confusion surrounding why HIV vaccine trials target people in high-risk communities. Some study participants saw this as unfair, from a social justice perspective.

Experimental HIV Vaccine Trials at Merck and Co. Caused More Infections
Trials of a once-promising experimental HIV vaccine were cut short in 2007 because the drug may have increased the likelihood of HIV infection rather than preventing it, according to a new study.

"We found that there is a general altruism towards HIV vaccine trials in these communities, and a feeling that people should participate 'for the greater good,'" says Newman. "But there is also a lot of overriding confusion and misunderstanding, which illustrates a clear need for medical researchers and health professionals to do a better job of communicating with at-risk communities before, during and after trials."

Newman will present related findings at this year's annual AIDS Vaccine Conference in Bangkok between September 12 to 15.

Source-Eurekalert